BACKGROUND α‐Fetoprotein (AFP) is a biomarker commonly used in the management of
patients with hepatocellular carcinoma (HCC), although the possible determinants of its …

The prognostic impact of serum α-fetoprotein (AFP) level in patients with hepatocellular
carcinoma (HCC) is controversial. This study aimed to investigate the predictive ability of …

AIM: To explore the relationship between α-fetoprotein (AFP) and various clinicopathological
variables and different staging system of hepatocellular carcinoma (HCC) thoroughly …

Alpha fetoprotein (AFP) is the most widely used diagnostic and prognostic serum biomarker
for hepatocellular carcinoma (HCC). Despite its wide clinical use, a systematic …

Background and Aims The prognostic ability of α-fetoprotein (AFP) for patients with
hepatocellular carcinoma (HCC) was examined by using different cutoff values. The optimal …

Serum a-fetoprotein (AFP), a well-established biomarker for hepatocellular carcinoma
(HCC), increases the sensitivity of ultrasound-based surveillance programs for early stage …

Background Serum α‐fetoprotein (AFP) is the most important tumor marker for
hepatocellular carcinoma (HCC). The reported predictive accuracy of AFP for HCC widely …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) can result from hepatitis C virus
(HCV)-related liver disease and is the fastest-growing cause of cancer-related death in the …

Objectives The role of serum α-fetoprotein (AFP) measurements in the diagnosis of
hepatocellular carcinoma (HCC) remains controversial. Some guidelines have advised …

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer‐related
deaths globally due, in part, to the majority of patients being diagnosed with intermediate or …